Journey Medical

Update in progress

DERM (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing dermatology products in the United States. Its marketed therapies include Qbrexza for primary axillary hyperhidrosis; Accutane (isotretinoin) for severe nodular acne; Amzeeq (minocycline) for inflammatory acne; Zilxi and Emrosi for rosacea; Exelderm for fungal infections; Luxamend for moist wound healing. Formerly Coronado Dermatology, Inc., founded in 2014 and based in Scottsdale, Arizona.

Company score

Sentiment: 0.53; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.36; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive